GlassScriptPhysician profile
Vincent T Buckman
NPI 1346248762
$8,815.18
in general payments reported to CMS, 2019-2025
43 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $139 · 2021: $1,182 · 2022: $1,838 · 2023: $1,183 · 2024: $1,804 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,200.10 | 2019-2024 | Xarelto |
| Abbvie INC. | $1,082.85 | 2022-2025 | Qulipta, Vraylar |
| Boston Scientific Corporation | $1,064.91 | 2021-2025 | Watchman Flx, Farapulse |
| Bayer Healthcare Pharmaceuticals INC. | $879.28 | 2021-2024 | |
| Glaxosmithkline, LLC. | $702.19 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.22 | 2019-2022 | |
| Pfizer INC. | $461.84 | 2019-2025 | |
| Novo Nordisk INC | $448.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Paratek Pharmaceuticals, INC. | $277.87 | 2021-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $249.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $212.58 | 2024-2025 | Voquezna |
| Amgen INC. | $156.76 | 2019-2025 | Evenity, Prolia, Repatha |
| Radius Health, INC. | $144.18 | 2019-2024 | Tymlos |
| Lilly USA, LLC | $139.28 | 2022-2025 | Jardiance, Emgality, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $134.95 | 2022-2024 | Rexulti |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.46 | 2019 | |
| Inspire Medical Systems, INC. | $120.58 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $115.00 | 2022 | |
| Silk Road Medical, INC. | $108.69 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Organogenesis INC. | $89.39 | 2022-2023 | Puraply |
| Mannkind Corporation | $59.40 | 2022 | |
| Integra Lifesciences Corporation | $57.68 | 2019-2020 | |
| Medtronic USA, INC. | $47.33 | 2019 | |
| Xeris Pharmaceuticals, INC. | $40.77 | 2023-2024 | Gvoke Hypopen |
| Covidien LP | $37.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.16 | 2025 | |
| Novartis Pharmaceuticals Corporation | $31.81 | 2024-2025 | |
| Ucb, INC. | $25.70 | 2021 | |
| Dexcom, INC. | $24.68 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $21.76 | 2022 | |
| Axsome Therapeutics, INC. | $20.95 | 2024 | Auvelity |
| Kci USA, INC. | $19.84 | 2022 | |
| Acorda Therapeutics, INC | $19.46 | 2022 | |
| Astellas Pharma US INC | $18.88 | 2025 | Veozah |
| Lundbeck LLC | $18.45 | 2023 | Rexulti |
| Inari Medical, INC. | $16.90 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alnylam Pharmaceuticals INC. | $15.86 | 2022 | |
| Antares Pharma, INC. | $15.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.71 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2022 | |
| Allergan, INC. | $14.68 | 2022 | |
| Abbott Laboratories | $14.52 | 2024 | Jot Dx |
| Shield Therapeutics INC | $13.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Buckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.